Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 for prevention of postoperative venous thromboembolism in ovarian cancer surgery
CTR20240133Phase 2Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2004 in venous thromboembolism (VTE), ovarian cancer, sponsored by Beijing Shengdi Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
SHR-2004
03
Conditions
venous thromboembolism (VTE)ovarian cancer
Beyond the preview
Go deeper on CTR20240133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240133.